Epitalon EMA vs FDA Approach: Regulatory Status, Safety, and What Patients Need to Know

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

What is epitalon?

Epitalon (also spelled epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (H-Ala-Glu-Asp-Gly-OH), molecular weight about 390 g/mol as the free base and about 450 g/mol as the acetate [1]. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland; FDA treats epitalon and epithalamin as different substances, so studies of epithalamin are not studies of epitalon [1]. FDA says epitalon first appears to have been synthesized in 1999 [1].

It is sold online as research-use-only vials of 10 mg to 50 mg, as capsules and as oral sprays, and promoted as an anti-aging peptide that lengthens telomeres [1].

Does the FDA or the EMA approve epitalon?

No. Epitalon is not an FDA-approved drug and is not a component of one [1]. FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].

The compound did hold one regulatory status. FDA granted epitalon an orphan drug designation for retinitis pigmentosa on September 2, 2010, and the designation was withdrawn on January 6, 2016 [1].

A 2015 analysis identified epitalon in two illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa [7]. A Kentucky pharmacy was reported by the US Attorney's office to have compounded and distributed epitalon products from October 25, 2018 to April 1, 2020, and FDA found no pharmacy that compounds it and no outsourcing facility reporting it [1].

Can pharmacies compound epitalon in the United States?

Epitalon does not appear on any FDA list that would let a compounder use it routinely. FDA's page on bulk substances that may present significant safety risks (content dated 04/22/2026) lists epitalon in the 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them [8]. FDA's stated concerns are that it 'has not identified safety-related information regarding epitalon for the proposed route of administration', so it lacks sufficient information to know whether the drug would cause harm, and that injectable peptides may pose immunogenicity risk from aggregation and impurities [8]. FDA also states that removal from category 2 was not a finding that epitalon is safe [8].

Epitalon appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), and it does not appear on FDA's list for outsourcing facilities (updated March 21, 2025); the category 1 policy of generally taking no action against compounders does not cover it [2][3][4].

In a July 2026 briefing document, FDA staff proposed that neither epitalon free base nor epitalon acetate be added to the pharmacy bulks list [1]. FDA evaluated only the use for insomnia and did not evaluate the other nominated uses, such as anti-aging and telomere lengthening, for lack of information [1]. Staff cited limited characterization, limited historical use, no evidence of effectiveness for insomnia, no clinical safety data, an immunogenicity concern for subcutaneous injection, and the existence of many FDA-approved insomnia drugs [1]. The nominated products were 10 mg/mL and 3000 microgram/mL subcutaneous injections [1].

FDA's Pharmacy Compounding Advisory Committee reviewed epitalon on July 24, 2026 and voted in favor of adding it to the bulks list, against staff's recommendation [5][6]. That vote is advice only and is not binding; epitalon is not on the list, and adding it requires formal rulemaking [6].

HHS has drafted a separate policy. The draft enforcement-discretion policy filed October 28, 2026 (Federal Register document 2026-22192, publication scheduled for October 30, 2026, comments due two weeks after publication) names epitalon among six peptides, alongside BPC-157, KPV, MOTS-c, Semax and TB-500 [6][9]. It covers epitalon acetate given by subcutaneous or intramuscular injection in intermittent courses [6]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it when the policy's conditions are met - for example a single active ingredient, a patient-specific prescription, a manufacturer registered with FDA and supplying a certificate of analysis, and the label statement 'This is a compounded drug product. Not for resale.' [6][9].

The draft is not an approval and does not put epitalon on any list [6]. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it if a safety signal or product quality issue arises [6]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [6].

What safety data exist for epitalon?

FDA found no clinical study that assessed epitalon's safety [1]. Its search of the adverse-event database through December 8, 2025 and of the food and supplement complaint system through December 5, 2025 retrieved no epitalon reports, and FDA concluded there are no clinical data supporting epitalon's safety [1]. FDA found no pharmacokinetic data for epitalon [1].

One small study gave no safety data, and a Russian-language abstract claimed 'no side effects' without giving a dose, a route or a number of people [1]. FDA raised an immunogenicity concern for subcutaneous injection [1].

The mechanism work is mostly laboratory work. In cultured human fetal fibroblasts that lack telomerase, epitalon induced telomerase activity and telomere elongation [10]. In people, small studies report that it raises melatonin output in older or pineal-impaired subjects [1]. FDA found that how epitalon changes melatonin in the body is unknown, and warned that epitalon activates telomerase and lengthens telomeres, that longer telomeres are generally linked to higher cancer risk, and that the peptide therefore has a mechanistic potential to be carcinogenic; the mouse studies of cancer and chromosome damage were too limited - one fixed dose, female mice only, short exposure - to show safety [1].

What human studies of epitalon exist?

FDA found only three human studies of epitalon: two sublingual studies in night-shift workers and one eye-injection study in retinitis pigmentosa. None was in insomnia [1].

One of the sublingual studies was placebo-controlled, in healthy women aged 40 to 50, mostly night-shift workers; 75 were enrolled, and 40 with low melatonin output were split into two groups of 20 [1]. Participants used a sublingual Ala-Glu-Asp-Gly spray delivering about 0.5 mg per day, or placebo, for 20 days [1]. Urinary 6-sulfatoxymelatonin rose about 1.7-fold with epitalon and did not change with placebo; 83% versus 25% were described as improved in mood and physical condition, but no sleep outcomes were measured, blinding was not specified, and the study was short and small [1].

In the older retinitis pigmentosa study, the abstract reports a positive clinical effect in 90% of patients with degenerative retinal lesions, but gives no sample size or design details to judge the result [11]. Epitalon was injected beside the eye in that study [1]. No adequately powered randomized trial has established efficacy [12].

A 2026 narrative review, searching through September 22, 2026, concluded that human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa, that pharmacokinetic, dose-ranging and long-term safety data are inadequate, and that epitalon is 'biologically active but clinically unproven' [12].

What dose is used?

There is no approved dose [1]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles (one site suggested every 4 months), which is marketing rather than evidence [1]. The human studies FDA found used a sublingual spray delivering about 0.5 mg per day for 20 days, and a parabulbar (beside the eye) injection for retinitis pigmentosa [1].

Is epitalon on the WADA Prohibited List?

Epitalon is not named in WADA's 2026 Prohibited List or in the 2027 tracked-changes version dated 26 August 2026 [13][14]. Class S0 prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and the list gives BPC-157 only as an example, prefaced by 'including but not limited to' [13][14]. The list does not say whether epitalon falls under class S0, so it neither names epitalon nor settles its status.